mk2 Biotechnologies develops, produces and investigates peptides & proteins using a revolutionary synthesis technology.
Current Status
We have established development partnerships with stock-listed corporations such as Wacker and Sartorius and are developing a set of high-potential products and processes ourselves. Additionally, we have achieved the tech ransfer to steel to ensure that our technologies are indeed scalable and can massively reduce the production cost.
Problem or Opportunity
Highly potent bioactive peptides and proteins cannot be produced at sufficiently low cost and high quality, so that their application in large-scale applications is impossible or limited to high-margin-areas only. However, that class of products, if available, could have the potential to enable novel products, solutions and applications in several industries.
Solution (product or service)
We developed a production plattform technology that enables the production of the required products at large scales and low cost outperforming established technologies by 3-5 orders of magnitude in cost. Respectively, we finally provide the manufacturing technologies required to enable peptides & proteins for mass applications.
Business model
Adressing a SAM of greater 1Bn USD, we position ourselves as technology developers and providers, that develops and optimizes manufacturing processes and scales them up. However, we do not see ourselves as a CMO, but would provide the developed technologies under license to be commercialized by partners. That way, we can exploit a large part of the economic market potential and still focus on our core competencies.
Incubation/Acceleration programs accomplishment
Several. Amongst others: Mass Challange Switzerland, Plug&Play Food, German Accelerator, Xpreneurs, BioTools Innovator
